MarketPulse

reproxalap

24 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

ALDX Stock Crashes 71% After FDA Rejects Lead Drug; Class Action Lawsuit Filed

Aldeyra Therapeutics stock plummets 71% following FDA rejection of reproxalap for dry eye disease. Class action lawsuit filed; investor deadline May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ALDX Stock Crashes 71% After FDA Rejects Reproxalap; Securities Probe Launched

Aldeyra Therapeutics plummets 71% after FDA rejects lead dry eye drug. Securities litigation firm investigating potential investor claims following efficacy concerns.
ALDXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Stock Plummets 71% After FDA Rejects Lead Drug; Law Firm Launches Investigation

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.
ITDNOWALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Aldeyra Stock Plummets 70% After FDA Rejection; Law Firm Eyes Securities Claims

Johnson Fistel investigates Aldeyra Therapeutics after FDA rejects lead drug reproxalap. Stock tumbles over 70% on March 17, 2026 announcement.
ALDXstock declineinvestor losses